A Voxel Wise Analysis of Cerebral Beta Amyloid Retention in Healthy Controls and Subjects with Amnestic Mild Cognitive Impairment and Alzheimer's Disease.
- Author:
Yeani CHO
1
;
Yoo Hyun UM
;
Tae Won KIM
;
Ho Jun SEO
;
Jong Hyun JEONG
;
Seung Chul HONG
;
Jin Hee HAN
;
In Ho BAEK
;
Hyun Kook LIM
Author Information
1. Department of Psychiatry, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, Korea. drblues@catholic.ac.kr
- Publication Type:Original Article
- Keywords:
β-amyloid;
Positron emission tomography;
18F-florbetaben;
Alzheimer's disease
- MeSH:
Alzheimer Disease*;
Amyloid*;
Brain;
Frontal Lobe;
Gyrus Cinguli;
Humans;
Injections, Intravenous;
Limbic Lobe;
Mild Cognitive Impairment*;
Occipital Lobe;
Parietal Lobe;
Plaque, Amyloid;
Positron-Emission Tomography;
Prefrontal Cortex;
Temporal Lobe
- From:Journal of Korean Geriatric Psychiatry
2016;20(2):75-79
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: The purpose of the study was to compare cortical amyloid deposition using 18F-florbetaben and positron emission tomography (PET) in healthy controls and subjects with amnestic mild cognitive impairment (aMCI) and Alzheimer's disease (AD). METHODS: We investigated 25 patients : 10 age-matched healthy controls, 10 patients with aMCI and 5 with AD. All participants underwent PET after intravenous injection of 300 MBq of 18F-florbetaben. The 90 min post-injection brain PET data were analysed using statistical parametric mapping. RESULTS: When compared to healthy controls, amyloid deposition was significantly higher in frontal lobe medial frontal gyrus, limbic lobe posterior cingulate, parietal lobe precuneus, sub-loba insula, temporal lobe superior temporal gyrus, parietal lobe inferior parietal lobule, temporal lobe middle temporal gyrus, parietal lobe supramarginal gyrus, occipital lobe middle temporal gyrus of patient group (family wise error correction p<0.05). CONCLUSION: These results indicate 18F-florbetaben to be an efficacious β-amyloid-targeted tracer. Subjects with aMCI, AD could be easily differentiated from healthy controls by assessment of the PET data.
